UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 186

Sortiert nach

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The New England journal of medicine, 2019-12, Vol.381 (26), p.2506-2518

2019

Link zum Volltext

Verfügbarkeit prüfen

Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?

European urology, 2007-05, Vol.51 (5), p.1202-1216

2007

Link zum Volltext

Verfügbarkeit prüfen

The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation

European urology, 2011-07, Vol.60 (1), p.106-117

2011

Link zum Volltext

Verfügbarkeit prüfen

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis

BJU international, 2022-04, Vol.129 (4), p.423-433

2022

Link zum Volltext

Verfügbarkeit prüfen

Response assessment using [68Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer

The Prostate, 2020-01, Vol.80 (1), p.74-82

2020

Link zum Volltext

Verfügbarkeit prüfen

Human Dermis Harbors Distinct Mesenchymal Stromal Cell Subsets

Journal of investigative dermatology, 2012-03, Vol.132 (3), p.563-574

2012

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

Targeted oncology, 2020-06, Vol.15 (3), p.301-315

2020

Link zum Volltext

Verfügbarkeit prüfen

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation

Cancers, 2021-03, Vol.13 (7), p.1487

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [ 68 Ga]Ga-PSMA-11-PET Examinations

Cancers, 2024-04, Vol.16 (8), p.1514

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

European journal of nuclear medicine and molecular imaging, 2020-03, Vol.47 (3), p.713-720

2020

Link zum Volltext

Verfügbarkeit prüfen

Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer

Human pathology, 2014-04, Vol.45 (4), p.674-682

2014

Link zum Volltext

Verfügbarkeit prüfen

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Current oncology (Toronto), 2021-09, Vol.28 (5), p.3692-3704

2021

Link zum Volltext

Verfügbarkeit prüfen

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer

The Journal of urology, 2016-04, Vol.195 (4 Pt 1), p.1120

2016

Link zum Volltext

Verfügbarkeit prüfen

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (5), p.1751-1756

2004

Link zum Volltext

Verfügbarkeit prüfen

418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A448-A448

2021

Link zum Volltext

Verfügbarkeit prüfen

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Clinical genitourinary cancer, 2018-02, Vol.16 (1), p.e223-e231

2018

Link zum Volltext

Verfügbarkeit prüfen

Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Cancers, 2021-05, Vol.13 (10), p.2489

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

European urology open science (Online), 2022-11, Vol.45, p.12-22

2022

Link zum Volltext

Verfügbarkeit prüfen

Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009–2013

European urology, 2018-04, Vol.73 (4), p.635-636

2018

Link zum Volltext

Verfügbarkeit prüfen

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations

Journal of personalized medicine, 2021-09, Vol.11 (9), p.917

2021

Link zum Volltext

Verfügbarkeit prüfen

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

European urology open science (Online), 2021-08, Vol.30, p.63-66

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognostic effect of serum and tissue YKL-40 levels in bladder cancer

Urologic oncology, 2014-07, Vol.32 (5), p.663-669

2014

Link zum Volltext

Verfügbarkeit prüfen

Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation

The Prostate, 2002-06, Vol.52 (1), p.43-58

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 186

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(173)

Publikationsform

Artikel
(182)
Bücher
(4)

Sprache

Englisch
(175)
Japanisch
(18)
Deutsch
(12)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?

The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation

Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis

Response assessment using [68Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer

Human Dermis Harbors Distinct Mesenchymal Stromal Cell Subsets

Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry

Extracellular Vesicle-Associated Tissue Factor Activity in Prostate Cancer Patients with Disseminated Intravascular Coagulation

Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [ 68 Ga]Ga-PSMA-11-PET Examinations

Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks

Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer

Renal and Salivary Gland Functions after Three Cycles of PSMA-617 Therapy Every Four Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18

418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Response and Toxicity to the Second Course of 3 Cycles of 177Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

Re: Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals 2009–2013

Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer

Prognostic effect of serum and tissue YKL-40 levels in bladder cancer

Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation

Suchergebnisse filtern